German biotech firm Morphosys said this week its ABd Serotec division has licensed seven of its diagnostic HuCAL antibodies to Spanish biomarker company Proteomika for use in its Promonitor diagnostic.
Promonitor is designed to determine circulating levels of different drugs and the immune response they trigger in patients.
It plans to launch kits in the second quarter of this year containing the HuCAL antibodies that can help monitor certain biopharmaceutical therapies.
Currently, Proteomika offers tests that monitor patients treated with anti-TNF and anti-CD20 agents and is developing similar diagnostics for use with other biopharmaceutical families.
Terms of the license call for ABd Serotec to receive royalties for product sales.
Further financial details of the agreement were not disclosed.
In March 2008, Proteomika ordered a number of antibodies from Morphosys for biomarker research (GWDN 03/05/2008). At the time, the order made Proteomika among the largest customers for ABd Serotec's custom monoclonal services.